XML 71 R40.htm IDEA: XBRL DOCUMENT
v3.22.2

Collaborative and Other Relationships (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration |
|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat |  | $ | 78.6 |  |  | $ | 62.2 |  |  | $ | 155.6 |  |  | $ | 117.7 |
Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income |  | 39.3 |  |  | 31.1 |  |  | 77.8 |  |  | 58.8 |
Total sales and marketing expense incurred by the Lecanemab Collaboration |  | 23.4 |  |  | 4.3 |  |  | 39.3 |  |  | 10.0 |
Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 11.7 |  |  | 2.1 |  |  | 19.7 |  |  | 5.0 |
Summary of Activity Related to Aducanumab Collaboration | A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:
|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Total ADUHELM development expense |  | $ | 37.2 |  |  | $ | 42.1 |  |  | $ | 81.4 |  |  | $ | 89.1 |
Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income |  | 20.5 |  |  | 23.2 |  |  | 44.8 |  |  | 49.0 |
Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement |  | 40.8 |  |  | 125.6 |  |  | 135.8 |  |  | 237.4 |
Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income |  | 21.1 |  |  | 67.6 |  |  | 72.0 |  |  | 127.9 |
Total ADUHELM collaboration third-party milestones |  | — |  |  | 100.0 |  |  | — |  |  | 100.0 |
Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income |  | — |  |  | 45.0 |  |  | — |  |  | 45.0 |
Summary of Activity Related to Denali Therapeutics Collaboration | A summary of development expense related to this collaboration is as follows:
|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Total Denali collaboration development expense |  | $ | 23.2 |  |  | $ | 10.4 |  |  | $ | 38.1 |  |  | $ | 18.7 |
Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income |  | 13.2 |  |  | 6.2 |  |  | 22.1 |  |  | 11.2 |

X
- Definition Summary of Activity Related to Denali Therapeutics Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration